P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC.

Publication

P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC.

Krebs, Matthew G
;
Spicer, J
;
Steele, N
;
Talbot, D
;
Brada, M
;
Wilson, R
;
Jones, R
;
Basu, B
;
Dawes, J
;
Parmar, M
... show 6 more

Authors

Krebs, Matthew G
Spicer, J
Steele, N
Talbot, D
Brada, M
Wilson, R
Jones, R
Basu, B
Dawes, J
Parmar, M
Purchase, B
Turner, A
Hall, E
Tovey, H
Banerji, U
Yap, T

Affiliation

Experimental Cancer Medicine Team, the Christie NHS Foundation Trust, The University of Manchester and the Christie NHS Foundation Trust, Manchester/United Kingdom

Date

2017-01

Collections

All Christie Publications

Show all metadata

Files

Open access full text article

Adobe PDF, 172.63 KB

Type

Meetings and Proceedings

Citation

P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC. 2017, 12 (1):S1272 Journal of Thoracic Oncology

URI

http://hdl.handle.net/10541/620780